CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance

Nilufar Pashaee; Rachida Bouamar; Dennis A. Hesselink; Joke I. Roodnat; Ron H.N. Van Schaik; Willem Weimar; Teun Van Gelder

doi:10.1097/FTD.0b013e31821a7aa3

CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance

Nilufar Pashaee, Rachida Bouamar, Dennis A. Hesselink, Joke I. Roodnat, Ron H.N. Van Schaik, Willem Weimar, Teun Van Gelder^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Scopus)

Abstract

Background: The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance. Methods: To test whether this intrapatient variability is associated with an individual's CYP3A5 genotype, we measured the intrapatient variability in Tac clearance in a cohort of 208 kidney transplant recipients treated with Tac and mycophenolate mofetil. Results: Tac dose requirement was significantly higher in patients expressing CYP3A5. However, intraindividual variability of Tac clearance was not related to CYP3A5 genotype. Conclusions: Intraindividual variability in Tac clearance is not related to CYP3A5 genotype. Other factors, including patient adherence, may explain the variability in Tac clearance within an individual patient over time.

Original language	English
Pages (from-to)	369-371
Number of pages	3
Journal	Therapeutic Drug Monitoring
Volume	33
Issue number	3
DOIs	https://doi.org/10.1097/FTD.0b013e31821a7aa3
Publication status	Published - Jun 2011

Research programs

EMC MM-01-25-01
EMC MM-04-39-05
EMC OR-01-34-01

Access to Document

10.1097/FTD.0b013e31821a7aa3

http://hdl.handle.net/1765/33671

Cite this

@article{ad37e83baf1247a8b4bec2d8f2fafb8d,

title = "CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance",

abstract = "Background: The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance. Methods: To test whether this intrapatient variability is associated with an individual's CYP3A5 genotype, we measured the intrapatient variability in Tac clearance in a cohort of 208 kidney transplant recipients treated with Tac and mycophenolate mofetil. Results: Tac dose requirement was significantly higher in patients expressing CYP3A5. However, intraindividual variability of Tac clearance was not related to CYP3A5 genotype. Conclusions: Intraindividual variability in Tac clearance is not related to CYP3A5 genotype. Other factors, including patient adherence, may explain the variability in Tac clearance within an individual patient over time.",

author = "Nilufar Pashaee and Rachida Bouamar and Hesselink, \{Dennis A.\} and Roodnat, \{Joke I.\} and \{Van Schaik\}, \{Ron H.N.\} and Willem Weimar and \{Van Gelder\}, Teun",

year = "2011",

month = jun,

doi = "10.1097/FTD.0b013e31821a7aa3",

language = "English",

volume = "33",

pages = "369--371",

journal = "Therapeutic Drug Monitoring",

issn = "0163-4356",

publisher = "Lippincott Williams \& Wilkins",

number = "3",

}

TY - JOUR

T1 - CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance

AU - Pashaee, Nilufar

AU - Bouamar, Rachida

AU - Hesselink, Dennis A.

AU - Roodnat, Joke I.

AU - Van Schaik, Ron H.N.

AU - Weimar, Willem

AU - Van Gelder, Teun

PY - 2011/6

Y1 - 2011/6

N2 - Background: The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance. Methods: To test whether this intrapatient variability is associated with an individual's CYP3A5 genotype, we measured the intrapatient variability in Tac clearance in a cohort of 208 kidney transplant recipients treated with Tac and mycophenolate mofetil. Results: Tac dose requirement was significantly higher in patients expressing CYP3A5. However, intraindividual variability of Tac clearance was not related to CYP3A5 genotype. Conclusions: Intraindividual variability in Tac clearance is not related to CYP3A5 genotype. Other factors, including patient adherence, may explain the variability in Tac clearance within an individual patient over time.

AB - Background: The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance. Methods: To test whether this intrapatient variability is associated with an individual's CYP3A5 genotype, we measured the intrapatient variability in Tac clearance in a cohort of 208 kidney transplant recipients treated with Tac and mycophenolate mofetil. Results: Tac dose requirement was significantly higher in patients expressing CYP3A5. However, intraindividual variability of Tac clearance was not related to CYP3A5 genotype. Conclusions: Intraindividual variability in Tac clearance is not related to CYP3A5 genotype. Other factors, including patient adherence, may explain the variability in Tac clearance within an individual patient over time.

UR - http://www.scopus.com/inward/record.url?scp=80051770645&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31821a7aa3

DO - 10.1097/FTD.0b013e31821a7aa3

M3 - Article

C2 - 21566507

SN - 0163-4356

VL - 33

SP - 369

EP - 371

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

IS - 3

ER -

CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance

Abstract

Research programs

Access to Document

Other files and links

Fingerprint

Cite this